Olfr341 Inhibitors
Olfr341 inhibitors encompass a range of compounds that exert their inhibitory effects through various interactions with the G-protein-coupled receptor (GPCR) that Olfr341 represents. Some inhibitors function by binding directly to the active site, preventing the receptor from interacting with its natural ligands, thus impeding the signaling cascade that would normally follow receptor activation. Others work allosterically, binding to sites on the receptor other than the active site, which results in a conformational change that stabilizes the receptor in its inactive form. This stabilization directly diminishes Olfr341's functional activity, effectively silencing any potential downstream signaling. Additionally, certain inhibitors operate by obstructing G protein coupling or receptor dimerization, thereby inhibiting the intracellular communication pathways that Olfr341 might initiate.
Furthermore, inhibitors of Olfr341 also include molecules that antagonize the receptor indirectly by competing with ligands at the binding site or by preventing receptor conformational changes essential for signal transduction. These competitive inhibitors can cross-react with Olfr341 despite their primary targets being other GPCRs, due to the structural similarities shared among this receptor family. By blocking the ligand-receptor interaction or the subsequent activation of the receptor, these compounds ensure that Olfr341 remains in an inactive state, thereby reducing its ability to mediate physiological responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
This polyphenol found in green tea inhibits G-protein-coupled receptor (GPCR) signaling by preventing agonist-induced conformational changes. This would inhibit Olfr341 by blocking its ability to activate downstream signaling cascades. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor antagonist that can cross-react with related GPCRs, potentially inhibiting Olfr341 by blocking its ability to engage with its natural ligand or downstream effectors. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
A polysulfonated naphthylurea that inhibits various GPCRs by blocking G protein interaction. It could inhibit Olfr341 by preventing G protein coupling and subsequent intracellular signaling. | ||||||
Rauwolscine • HCl | 6211-32-1 | sc-200151 | 100 mg | $105.00 | ||
An α2-adrenergic receptor antagonist that might interact with Olfr341, leading to inhibition by blocking receptor activation and subsequent signaling. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A | 50 mg 500 mg | $68.00 $357.00 | 11 | |
Acts as an antagonist at various GPCRs. Clozapine could indirectly inhibit Olfr341 by blocking receptor conformational changes required for signal transduction. | ||||||
Methylene blue | 61-73-4 | sc-215381B sc-215381 sc-215381A | 25 g 100 g 500 g | $42.00 $102.00 $322.00 | 3 | |
A compound that interacts with GPCRs and can inhibit their function by interfering with receptor dimerization. This could lead to the inhibition of Olfr341 by preventing its proper assembly and signaling. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $60.00 $108.00 | 21 | |
Known to antagonize various GPCRs. Chlorpromazine could inhibit Olfr341 by blocking receptor activation and signal transduction. | ||||||
SCH 23390 | 125941-87-9 | sc-200408 sc-200408A | 5 mg 25 mg | $175.00 $719.00 | 2 | |
A dopamine receptor antagonist with potential cross-reactivity to other GPCRs. SCH-23390 could inhibit Olfr341 activity by competitive inhibition at the ligand-binding site. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
An α2-adrenergic receptor antagonist that may inhibit Olfr341 by blocking its activation, thus preventing downstream signaling events. | ||||||